BridgeBio Pharma, Inc. Common Stock
Veridion Score
Composite trend over time
Why is BBIO moving today?
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for BBIO.
BBIO insider activity
BridgeBio Pharma, Inc. Common Stock
3 insiders bought in the last 90 days
Net selling: -$79.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | 2026-06-24 | Cook Jennifer E. | Insider | sell | $70.00 | 37,167 | 8,383 | $2.6M | SEC Form 4 |
| 2026-06-24 | 2026-06-24 | Cook Jennifer E. | Insider | buy | $16.75 | 17,167 | 45,550 | $288K | SEC Form 4 |
| 2026-06-24 | 2026-06-24 | Cook Jennifer E. | Insider | buy | $8.45 | 20,000 | 28,383 | $169K | SEC Form 4 |
| 2026-06-24 | 2026-06-23 | Cook Jennifer E. | Insider | sell | $68.57 | 2,196 | 8,383 | $151K | SEC Form 4 |
| 2026-06-24 | 2026-06-23 | Valantine Hannah | Insider | sell | $68.57 | 2,196 | 9,259 | $151K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 140 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moBBIO contract awards, year to date.
Public federal awards linked to this ticker.
BBIO lobbying filings, year to date.
Registered lobbying filings matched to BridgeBio Pharma, Inc. Common Stock.